| Document Date: 2014-07-16 01:09:12
Open Document File Size: 1,06 MBShare Result on Facebook
City Boston / / Company Pfizer / AEs / MerckSerono SA / Scientific Advisory Group / Harvard Business School Press / Safety Advisory Group / / Country United States / / Event Product Issues / FDA Phase / Product Recall / / Facility Imperial College / Mario Negri Institute / / IndustryTerm medicinal product / TREATMENT OF PSORIASIS / / MedicalCondition aseptic meningitis / interstitial pneumonitis / common chronic / squamous dermatosis / Bells palsy / severe psoriasis / inflammatory polyradiculoneuropathy / disease / facial palsy / arthritis / serious disease / plaque psoriasis / non life-threatening diseases / GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS INDICATED FOR THE TREATMENT OF PSORIASIS / serious infections / chronic disease / erythema multiforme / adult psoriasis / severe chronic plaque psoriasis / Psoriasis / severe infections / Miller Fisher syndrome / infections / severe chronic plaque discoid psoriasis / psoriatic arthritis / syndrome / tuberculosis / / MedicalTreatment biologic therapies / retreatment / vaccinations / alternative therapies / / Organization Task Force / European Medicines Agency / Imperial College London / Harvard / European Commission / FDA / European Union / Mario Negri Institute / / Person David Luciani / Nan Wang / Diana Hughes / Alain Micaleff / Kimberley Hockley / Lawrence Phillips / / Position investigator / Physician / RT / appearance and social functioning Physician / Major / reporter / Judge / / Product Drug / SC / cyclosporine / RL / Raptiva / Tysabri / EU / / ProvinceOrState Massachusetts / / RadioStation Wave 1 / / Technology antibodies / / URL www.imi.europa.eu / www.imiprotect.eu / /
SocialTag |
Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 1 to Wave 1 Case Study Report 1:b:iii: Raptiva® (efalizumab)